Evidence map›Paper›PMID 40887112›Full record

ReviewBMJ open2025

Equivalence and non-inferiority trials in the evaluation of non-pharmacological interventions: rationale, challenges and recommendations.

Erland Axelsson

Abstract readReview
In one paragraph

Review in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Erland AxelssonDivision of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden erland.axelsson@ki.se.ORCID http://orcid.org/0000-0003-2562-2925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Direct comparisons of non-pharmacological interventions are becoming increasingly common. Many randomised clinical trials are designed to assess whether the effect of one intervention is either equivalent to, or not inferior to, that of a criterion standard. This article provides an accessible introduction to such equivalence and non-inferiority designs. Topics covered include the choice of hypothesis and comparator, the choice of equivalence or non-inferiority margin and the benefits and drawbacks of common methods of analysis. While equivalence and non-inferiority trials offer unique possibilities, there are also challenges. Some of these are particularly pronounced in the non-pharmacological setting, such as the difficulty in establishing margins informed by placebo effects and structural barriers to achieving sufficient statistical power. Under-recognised general threats to the equivalence and non-inferiority designs are also discussed, including the threat of poor intervention delivery leading to washed-out effects, the especially pronounced threat of rhetorical 'spin' in the reporting of inconclusive findings and the threat of increasingly indirect evidence due to the sequential change of criterion standards. Implications for the non-pharmacological field are brought to the reader's attention, and suggestions are given to improve methodological rigour.

Indexed as

Equivalence Trials as TopicRandomized Controlled Trials as TopicResearch DesignHumansClinical trialsEPIDEMIOLOGYSTATISTICS & RESEARCH METHODS

Identifiers

PMID40887112
PMCPMC12406809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.